Healthcare Demand Outstrips Supply in Noida: MOFSL Favors Medanta and Max

The Noida-Greater Noida region is rapidly evolving into a premier healthcare growth corridor in North India, driven by a massive demographic shift and industrial expansion. According to a recent report by Motilal Oswal Financial Services Ltd (MOFSL), the widening gap between patient demand and available medical infrastructure presents a significant opportunity for organized hospital players.

The Supply-Demand Gap in Western Uttar Pradesh

Despite recent capacity additions, the healthcare infrastructure in the Noida-Greater Noida belt remains significantly underpenetrated. Current estimates suggest there are only approximately 4,500 super-specialty beds serving the entire region, including adjoining cities in Western Uttar Pradesh.

This shortage is occurring alongside a massive population surge; the region’s population has grown at a 5.4% compound annual rate over the last five years, reaching roughly 1.3 million. The rise in IT services, manufacturing, data centers, and financial services has transformed Noida from a mere satellite town into a self-sustaining urban hub. This economic growth is fueling a high demand for specialized treatments in cardiology, oncology, diabetes care, and maternity services.

Expanding Catchment Areas and Infrastructure Tailwinds

The demand for high-end healthcare is no longer limited to local residents. Major hospital facilities are reporting significant patient inflows from East Delhi and neighboring districts such as Ghaziabad, Bulandshahr, and Aligarh.

The region's outlook is further bolstered by aggressive infrastructure development. Improved metro connectivity, expansive expressway networks, and the upcoming airport ecosystem are not only supporting industrial growth but are also positioning the area to become a potential hub for medical tourism. However, the sector faces one primary hurdle: the rising cost and intense competition for specialist doctors, which is putting pressure on operational profitability.

Investment Outlook: Medanta and Max Healthcare

MOFSL has identified two major players positioned to capitalize on this structural tailwind, issuing "Buy" ratings for both.

Medanta (Target Price: Rs 1,490): Medanta is benefiting from high patient volumes and improving realizations. While the company is expanding into diverse markets like Indore, Varanasi, and Mumbai, its Noida facility is a key driver. MOFSL expects the Noida unit to achieve EBITDA breakeven by the second half of FY27. The firm projects a robust 28% earnings CAGR over FY26-28, driven by capacity additions and hospital ramp-ups.

Max Healthcare (Target Price: Rs 1,260): Max Healthcare is noted for its high-acuity multi-specialty network and disciplined capital deployment. The company’s growth is supported by brownfield expansions and a strong digital patient acquisition strategy. MOFSL projects a consolidated revenue CAGR of 14% and a PAT (Profit After Tax) CAGR of 20% over FY26-28, supported by upcoming contributions from the Gurgaon greenfield project and expansions in Mohali and Nanavati.

Key Takeaways

  • Infrastructure Shortage: With only 4,500 super-specialty beds for a growing population of 1.3 million, the Noida-Greater Noida region faces a massive supply deficit.
  • Economic Drivers: Rapid industrialization in IT and manufacturing, coupled with improved connectivity, is driving demand for complex tertiary care.
  • Top Picks: MOFSL recommends Medanta and Max Healthcare, citing strong earnings growth potential and successful capacity expansion strategies.